Introduction
To study the genetic control of drug metabolism is often called pharmacogenetics. June 1981 therapeutic effects of a drug, e.g., anticoagulation or control of seizures, but also unwanted deleterious effects such as cancer or drug toxicity. The experimental system to be examined in detail in this chapter represents principally a genetic difference in receptor concentration; because of this defect, there are large genetic differences in the biotransformation and pharmacokinetics of certain drugs and other environmental pollutants, resulting in important differences in risk toward cancer, drug toxicity, mutation, and birth defects.
The general characteristics of the P-450-mediated monooxygenases and their coordinated enzymes 11 are first described. Secondly, the genetic differences in this model system in mice are examined. How these differences are associated with increased risk toward myelotoxicity and leukemia are then shown as examples. Numerous other conditions in mice associated with this genetic system are also listed. Lastly, current evidence for this genetic difference in man is briefly assessed.
Cytochrome P-450 Monooxygenases and Coordinated Enzymes
Many environmental pollutants and other foreign compounds are chemicals that are so hydrophobic they would remain in the body indefinitely were it not for the metabolism resulting in more polar derivatives. These drug-metabolizing enzyme systems, which are localized principally in the liver, are usually divided into two groups: phase I and phase II. During phase I metabolism, one or more polar groups (such as hydroxyl) are introduced into the hydrophobic parent molecule, thus allowing a handle, or position, for the phase II conjugating enzymes (such as UDP glucuronosyltransferase) to attack. The conjugated products are sufficiently polar, so that these detoxified chemicals are now excreted from the cell and from the body (1) .
One of the most interesting of the phase I enzyme systems is a group of enzymes known collectively as the cytochrome P-450-mediated monooxygenases. * The genetic relationship between these inducible enzymes and cancer or toxicity has been reviewed recently (3) . These membrane-bound enzyme systems are known to metabolize: polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BP) (ubiquitous in city smog, cigarette smoke and charcoalcooked foods) and biphenyl; halogenated hydrocarbons such as polychlorinated and polybrominated biphenyls, insecticides, and ingredients in soaps and deodorants; strong mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine and nitrosamines; aminoazo dyes and diazo compounds; N-acetylarylamines and nitrofurans; numerous aromatic amines, such as those found in hair dyes; nitro aromatics, and heterocyclics; wood terpenes; epoxides; carbamates; alkyl halides; safrole derivatives; certain fungal toxins and antibiotics; many of the chemo-*Cytochrome P-450 is defined as all forms of CO-binding hemoproteins associated with membrane-bound NADPHdependent monooxygenase activities. We define cytochrome P1-450 as all forms of CO-binding hemoprotein that increase in amount concomitantly with rises in induced AHH activity following polycyclic aromatic inducer treatment. In view of more than one such form of P,-450 (2), it is emphasized that this definition of PI-450 is simplistic. 12 therapeutic agents used to treat human cancer; most drugs; small chemicals such as benzene, thiocyanate, or ethanol; both endogenous and synthetic steroids; and other endogenous compounds such as biogenic amines, indoles, thyroxine, and fatty acids.
Evidence is growing that metabolism to reactive intermediates by cytochrome P-450-mediated monooxygenases is a prerequisite for mutagenesis, carcinogenesis, and toxicity caused by numerous drugs, polycyclic hydrocarbons, and other environmental pollutants. These reactive intermediates probably bind covalently to numerous cellular macromolecules. Most of this binding is probably random, but some may be nonrandom, i.e., specific binding dependent upon (5) .
The steady-state levels of these reactive electrophilic intermediates and, consequently, the rates at which they interact with the critical nucleophilic target are dependent upon a delicate balance between their generation and detoxication (Fig. 1) translocation of the inducer-receptor complex into the nucleus has now been demonstrated in the phenotypically responsive heterozygote and homozygote (8) . What happens in the nucleus is not yet known, but somehow the "message" (that these inducers of P1-450 exist in the cell's microenvironment) is received; the response is transcription of specific mRNA's, translation of these mRNA's into specific enzymes such as P1-450, and incorporation of P1-450 into cellular membranes. These induced enzymes may aid in detoxication or they may generate increased amounts ofreactive intermediates.
Genetic Differences in Myelotoxicity
Large doses of oral BP (100 to 125 mg/kg/day) produce bone marrow toxicity in AhdlAh(I mice, whereas the Ahb/Ahb and Ahb/Ah d individuals are extremely resistant to oral BP-induced marrow toxicity (9) . Figure 4 
Importance of the Route of Administration
In sum, the picture which has begun to emerge from numerous studies is categorized in idiopathic. Almost all of these agents mentioned peripheral lymphocytes have been cultured in the require P-450-mediated metabolism either for de-presence of mitogens and an inducer of AHH toxication or for metabolic potentiation to attain the activity such as 3-methylcholanthrene, in order to desired pharmacological effect. Chloramphenicol assess the human Ah phenotype. In spite of the and p,p'-DDT toxicity are not associated with the shortcomings with this assay method reviewed in Ah locus (unpublished data). We suggest that ref. (37) , a growing list of clinical disorders (Table  genetic differences between inbred strains of mice-3) appears to be associated with the human Ah with respect to marrow toxicity caused by these locus. various agents known (or suspected) to cause There clearly exists sufficient evidence that heriaplastic anemia in man-might be developed suc-table variation of AHH inducibility occurs in man. cessfully as a useful laboratory animal experimental Experimental difficulties, however, make it imposmodel. Needless to say, such a model should help sible at this time to be certain of whether AHH define the etiologic mechanisms, and thereby a induction is controlled by a single genetic locus or better understanding about treatment and preven-by two or more loci (i.e., polygenic). Until one can tion, for certain human aplastic anemias.
increase the range of fold inducibility of AHH With the use of 20 to 40 cc of drawn blood, activity and/or decrease the magnitude of day-to-day Table 3 . Human disorders that appear to be associated with the Ah locus.
